In conclusion, the greater expression of TRPM8 in primary and hormone naïve metastatic PCa, the large number of specific agonists [30], recent advances in the use of nanocarriers [36–38] and small molecules to deliver pharmacological compounds [39, 40], and, finally, the possibility to identify PCa patients who could benefit from the administration of TRPM8 agonists in combination with standard-of-care treatments, makes TRPM8 an extremely attractive target for developing more effective clinical protocols based on personalized PCa treatments. The gene discussed is TRPM8; the disease is posterior cortical atrophy.